Enoblituzumab Plus Retifanlimab or Tebotelimab in Head and Neck Cancer
Trial details
- Registry ID
- NCT04634825
- Phase
- Phase 2
The FDA approved Retifanlimab (INCMGA00012) on 22 Mar 2023.
Drug identity checked against registry records
Also recorded as INCMGA00012; MGA012; Zynyz
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| Enoblituzumab Plus Retifanlimab or Tebotelimab in Head and Neck CancerNCT04634825 | MacroGenics | Phase 2 | Terminated | 2022-07-29Actual |
| Combination Margetuximab, Retifanlimab, Tebotelimab, and Chemotherapy Phase 2/3 Trial in HER2+ Gastric/GEJ CancerNCT04082364 | MacroGenics | Phase 2, Phase 3 | Completed | 2024-01-15Actual |
| Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.NCT06072612 | BriaCell Therapeutics Corporation | Phase 3 | Recruiting | 2027-12Estimated |
| Date as reported | Drug / company | Event | Condition | Evidence |
|---|---|---|---|---|
| 2023-03-22Day | Retifanlimab | FDA original application approvalFDA approval decision | Not specified | Open original sourceRead source excerpt{"application_number": "BLA761334", "applicant_as_listed_by_fda": "INCYTE CORP", "brand_names": ["ZYNYZ"], "active_ingredients": ["RETIFANLIMAB-DLWR"], "submission_type": "ORIG", "submission_number": "1", "submission_status": "AP", "submission_status_date": "20230322", "matched_on": "registry alias equals FDA brand name and drug name is its active ingredient"} First seen: 06 Oct 2026 · Evidence last checked: 06 Oct 2026 |